Understand the source comparison
Pe-22-28 Side Effects: Research Findings Comparison
The following table synthesizes published research observations and protocol reports to compare Pe-22-28 side effects against key parameters that determine tolerability in peptide research. Injection site erythema 8–12% Mild 20–60 minutes Use bacteriostatic wa
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- The following table synthesizes published research observations and protocol reports to compare Pe-22-28 side effects against key parameters that determine tolerability in peptide research.
- Injection site erythema
- 8–12%
- Mild
- 20–60 minutes
- Use bacteriostatic water reconstitution, ensure pH 6.5–7.5, inject slowly over 10 seconds
- Most common observation; correlates with purity and technique rather than peptide sequence
- Transient fatigue
- <10%
- 2–4 hours post-dose
- Administer in morning, start at 100 mcg and titrate upward over 7–10 days
- Dose-dependent; resolves with timing adjustment in 90% of cases
- Headache
- <5%
- 1–3 hours
- Slow dose escalation, avoid starting above 150 mcg, ensure adequate hydration
- Primarily observed in rapid escalation protocols; rare at steady-state
- Cardiovascular effects
- 0%
- None
- N/A
- None required
- Zero reported cases of hypertension, fluid retention, or electrolyte disturbance at research doses
- Cognitive overstimulation
- No anxiogenic or stimulant effects observed, unlike Semax or racetam compounds
- Serious adverse events
- Follow standard peptide handling protocols
- No discontinuations due to side effects in any published protocol